Company intelligence / Profile preview

MMJ International Holdings

Providence, Rhode Island, United Statesmmjih.com ↗

Ownership: Private
Development stage: Other

Overview

MMJ International Holdings is advancing plant-derived cannabinoid therapeutics, with its lead candidate, a soft gelatin capsule containing THC and CBD ("MMJ‑002"), receiving Orphan Drug Designation from the FDA for Huntington’s disease. The company has submitted an IND application to the FDA and is preparing to initiate a Phase 2 clinical trial targeting chorea in Huntington’s disease. Regulatory delays due to DEA restrictions have led the company to expand operations internationally while continuing U.S. regulatory engagement[4][6].

Therapeutic areas: Neurology
Modalities: Small molecule (cannabinoids)Botanical drug product (plant-derived cannabinoids)
Industry: Biotech

Drug pipeline

1 asset

MMJ-002

Partnerships

No major pharmaceutical partnerships publicly disclosed; collaborates with leading cannabinoid scientists globally[1][2].

Beyond the preview

Go deeper on MMJ International Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMJ International Holdings.